↓ Skip to main content

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, June 2019
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)

Mentioned by

news
3 news outlets
twitter
11 tweeters
wikipedia
1 Wikipedia page

Citations

dimensions_citation
169 Dimensions

Readers on

mendeley
150 Mendeley